MA43822A - Compositions et procédés de synthèse de phosphoramidite et d'oligonucléotides - Google Patents
Compositions et procédés de synthèse de phosphoramidite et d'oligonucléotidesInfo
- Publication number
- MA43822A MA43822A MA043822A MA43822A MA43822A MA 43822 A MA43822 A MA 43822A MA 043822 A MA043822 A MA 043822A MA 43822 A MA43822 A MA 43822A MA 43822 A MA43822 A MA 43822A
- Authority
- MA
- Morocco
- Prior art keywords
- phosphoramidite
- oligonucleotides
- synthesis
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
- C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
- C07F9/65844—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring the phosphorus atom being part of a five-membered ring which may be condensed with another ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662307542P | 2016-03-13 | 2016-03-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA43822A true MA43822A (fr) | 2018-11-28 |
Family
ID=59852024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA043822A MA43822A (fr) | 2016-03-13 | 2017-03-13 | Compositions et procédés de synthèse de phosphoramidite et d'oligonucléotides |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11407775B2 (fr) |
| EP (1) | EP3430019A4 (fr) |
| JP (3) | JP7286320B2 (fr) |
| CN (2) | CN108779132B (fr) |
| AU (3) | AU2017234150B2 (fr) |
| CA (1) | CA3015823A1 (fr) |
| IL (1) | IL261247A (fr) |
| MA (1) | MA43822A (fr) |
| WO (1) | WO2017160741A1 (fr) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102282155B (zh) | 2008-12-02 | 2017-06-09 | 日本波涛生命科学公司 | 磷原子修饰的核酸的合成方法 |
| RU2612521C2 (ru) | 2009-07-06 | 2017-03-09 | Онтории, Инк. | Новые пролекарства нуклеиновых кислот и способы их применения |
| JP5868324B2 (ja) | 2010-09-24 | 2016-02-24 | 株式会社Wave Life Sciences Japan | 不斉補助基 |
| CN103796657B (zh) | 2011-07-19 | 2017-07-11 | 波涛生命科学有限公司 | 合成官能化核酸的方法 |
| KR102213609B1 (ko) | 2012-07-13 | 2021-02-08 | 웨이브 라이프 사이언시스 리미티드 | 키랄 제어 |
| PL2872485T3 (pl) | 2012-07-13 | 2021-05-31 | Wave Life Sciences Ltd. | Asymetryczna grupa pomocnicza |
| JPWO2015108047A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
| JPWO2015108048A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| BR112016016400A2 (pt) | 2014-01-16 | 2017-10-03 | Wave Life Sciences Ltd | Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos |
| IL320434A (en) | 2015-07-22 | 2025-06-01 | Wave Life Sciences Ltd | Oligonucleotide preparations and methods |
| IL295755A (en) | 2015-10-09 | 2022-10-01 | Wave Life Sciences Ltd | Oligonucleotide compositions and methods thereof |
| CN108779132B (zh) * | 2016-03-13 | 2022-04-15 | 波涛生命科学有限公司 | 用于亚磷酰胺和寡核苷酸合成的组合物和方法 |
| EP3452596A4 (fr) | 2016-05-04 | 2020-03-18 | Wave Life Sciences Ltd. | Compositions d'oligonucléotides et procédés associés |
| JP2019520339A (ja) | 2016-06-03 | 2019-07-18 | ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． | オリゴヌクレオチド、その組成物および方法 |
| WO2017220751A1 (fr) | 2016-06-22 | 2017-12-28 | Proqr Therapeutics Ii B.V. | Oligonucléotides d'édition d'arn monocaténaire |
| CN110352244B (zh) | 2016-09-01 | 2023-03-21 | ProQR治疗上市公司Ⅱ | 化学修饰的编辑rna的单链寡核苷酸 |
| US11873316B2 (en) | 2016-11-23 | 2024-01-16 | Wave Life Sciences Ltd. | Compositions and methods for phosphoramidite and oligonucleotide synthesis |
| JP2020522510A (ja) | 2017-06-02 | 2020-07-30 | ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． | オリゴヌクレオチド組成物及びその使用方法 |
| CA3065523A1 (fr) | 2017-06-02 | 2018-12-06 | Wave Life Sciences Ltd. | Compositions d'oligonucleotides et leurs procedes d'utilisation |
| US11718638B2 (en) | 2017-06-21 | 2023-08-08 | Wave Life Sciences Ltd. | Compounds, compositions and methods for synthesis |
| EP3664816A4 (fr) | 2017-08-08 | 2021-05-19 | Wave Life Sciences Ltd. | Compositions oligonucléotidiques et procédés associés |
| CA3072110A1 (fr) | 2017-09-18 | 2019-03-21 | Wave Life Sciences Ltd. | Technologies de preparation d'oligonucleotides |
| EP3694530A4 (fr) | 2017-10-12 | 2021-06-30 | Wave Life Sciences Ltd. | Compositions d'oligonucléotides et procédés associés |
| SG11202009877XA (en) | 2018-04-12 | 2020-11-27 | Wave Life Sciences Ltd | Oligonucleotide compositions and methods of use thereof |
| US12391942B2 (en) | 2018-05-11 | 2025-08-19 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| GB201808146D0 (en) | 2018-05-18 | 2018-07-11 | Proqr Therapeutics Ii Bv | Stereospecific Linkages in RNA Editing Oligonucleotides |
| JP2022525541A (ja) | 2019-03-20 | 2022-05-17 | ウェイブ ライフ サイエンシズ リミテッド | オリゴヌクレオチド調製に有用な技術 |
| MX2022014606A (es) | 2020-05-22 | 2023-03-08 | Wave Life Sciences Ltd | Composiciones de oligonucleótidos bicatenarios y métodos relacionados con las mismas. |
| CN112898363B (zh) * | 2021-01-25 | 2024-06-04 | 苏州金唯智生物科技有限公司 | 一种亚磷酰胺单体组合物及其制备方法和应用 |
| EP4479535A1 (fr) | 2022-02-14 | 2024-12-25 | ProQR Therapeutics II B.V. | Oligonucléotides guides pour l'édition d'acides nucléiques dans le traitement de l'hypercholestérolémie |
| US20260027237A1 (en) | 2022-07-15 | 2026-01-29 | Proqr Therapeutics Ii B.V. | Chemically modified oligonucleotides for adar-mediated rna editing |
| JP2025524566A (ja) | 2022-07-15 | 2025-07-30 | プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ | Ａｄａｒ媒介ｒｎａ編集のためのオリゴヌクレオチドおよびその使用 |
| GB202215614D0 (en) | 2022-10-21 | 2022-12-07 | Proqr Therapeutics Ii Bv | Heteroduplex rna editing oligonucleotide complexes |
| WO2024110565A1 (fr) | 2022-11-24 | 2024-05-30 | Proqr Therapeutics Ii B.V. | Oligonucléotides antisens pour le traitement de l'hémochromatose hfe héréditaire |
| GB202218090D0 (en) | 2022-12-01 | 2023-01-18 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency |
| AU2023390632A1 (en) | 2022-12-09 | 2025-07-10 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of cardiovascular disease |
| GB202300865D0 (en) | 2023-01-20 | 2023-03-08 | Proqr Therapeutics Ii Bv | Delivery of oligonucleotides |
| WO2024175550A1 (fr) | 2023-02-20 | 2024-08-29 | Proqr Therapeutics Ii B.V. | Oligonucléotides antisens pour le traitement d'une maladie cardiovasculaire athérosclérotique |
| GB202304363D0 (en) | 2023-03-24 | 2023-05-10 | Proqr Therapeutics Ii Bv | Chemically modified antisense oligonucleotides for use in RNA editing |
| EP4689110A1 (fr) | 2023-03-24 | 2026-02-11 | ProQR Therapeutics II B.V. | Oligonucléotides antisens pour le traitement de troubles neurologiques |
| EP4688143A1 (fr) | 2023-03-27 | 2026-02-11 | ProQR Therapeutics II B.V. | Oligonucléotides antisens pour traitement des maladies du foie |
| TW202516003A (zh) | 2023-06-16 | 2025-04-16 | 荷蘭商Ｐｒｏｑｒ治療上市公司Ｉｉ | 用於治療神經退化性疾病之反義寡核苷酸 |
| WO2025015335A1 (fr) | 2023-07-13 | 2025-01-16 | Korro Bio, Inc. | Oligonucléotides d'édition d'arn et leurs utilisations |
| WO2025051946A1 (fr) | 2023-09-07 | 2025-03-13 | Proqr Therapeutics Ii B.V. | Oligonucléotides antisens pour le traitement de troubles métaboliques |
| WO2025096809A1 (fr) | 2023-10-31 | 2025-05-08 | Korro Bio, Inc. | Oligonucléotides comprenant des liaisons internucléotidiques de phosphoramidate |
| WO2025104239A1 (fr) | 2023-11-16 | 2025-05-22 | Proqr Therapeutics Ii B.V. | Oligonucléotides antisens pour le traitement de galactosémie classique |
| WO2025128799A1 (fr) | 2023-12-12 | 2025-06-19 | Korro Bio, Inc. | Oligonucléotides d'édition d'arn double brin et leurs utilisations |
| WO2025132708A1 (fr) | 2023-12-20 | 2025-06-26 | Proqr Therapeutics Ii B.V. | Oligonucléotides antisens pour traitement de maladie de huntington |
| GB202404661D0 (en) | 2024-04-02 | 2024-05-15 | Proqr Therapeutics Ii Bv | Antisense oligoncleotides for the treatment of liver disease |
| WO2025224230A1 (fr) | 2024-04-25 | 2025-10-30 | Proqr Therapeutics Ii B.V. | Oligonucléotides antisens pour traitement de la stéatose hépatique |
| GB202410081D0 (en) | 2024-07-11 | 2024-08-28 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of cardiovascular disease |
| WO2026022136A1 (fr) | 2024-07-23 | 2026-01-29 | Proqr Therapeutics Ii B.V. | Oligonucléotides antisens pour le traitement de troubles métaboliques |
| WO2026050243A1 (fr) | 2024-08-26 | 2026-03-05 | Korro Bio, Inc. | Oligonucléotides conjugués à des fractions galnac pour édition d'arn |
| WO2026060374A2 (fr) | 2024-09-16 | 2026-03-19 | Proqr Therapeutics Ii B.V. | Oligonucléotides antisens pour le traitement de troubles neurologiques |
| WO2026068781A1 (fr) | 2024-09-30 | 2026-04-02 | Proqr Therapeutics Ii B.V. | Oligonucléotides antisens pour traitement des maladies hépatiques |
| CN119264195B (zh) * | 2024-12-12 | 2025-04-08 | 天津奥瑞芙生物医药有限公司 | 一种亚磷酰胺单体的纯化方法 |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0249777B2 (ja) * | 1981-09-21 | 1990-10-31 | Mitsubishi Gas Chemical Co | Shirikagerunosaiseiho |
| US5646265A (en) | 1990-01-11 | 1997-07-08 | Isis Pharmceuticals, Inc. | Process for the preparation of 2'-O-alkyl purine phosphoramidites |
| US7101993B1 (en) | 1990-01-11 | 2006-09-05 | Isis Pharmaceuticals, Inc. | Oligonucleotides containing 2′-O-modified purines |
| DE69412704T2 (de) | 1993-06-10 | 1999-02-04 | Idemitsu Petrochemical Co., Ltd., Tokio/Tokyo | Spritzgiessform |
| US6180766B1 (en) * | 1993-12-02 | 2001-01-30 | Raymond F. Schinazi | Nucleosides and oligonucleotides containing boron clusters |
| US5571937A (en) * | 1994-05-13 | 1996-11-05 | Sloan-Kettering Institute For Cancer Research | Complementary DNA and toxins |
| WO1997009443A1 (fr) * | 1995-09-05 | 1997-03-13 | Michigan State University | Procede d'isolement et de purification du taxol et des taxanes a partir du taxus spp |
| US5869696A (en) | 1996-04-22 | 1999-02-09 | Beckman Instruments, Inc. | Universal solid supports and methods for their use |
| US6867294B1 (en) | 1998-07-14 | 2005-03-15 | Isis Pharmaceuticals, Inc. | Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages |
| CA2458393A1 (fr) * | 2001-08-24 | 2003-03-06 | Massachusetts Institute Of Technology | Reactifs facilitant la purification de composes synthetises sur un support solide |
| JP4348044B2 (ja) | 2002-02-12 | 2009-10-21 | 株式会社キラルジェン | 立体規則性の高いジヌクレオシドホスホロチオエートの製造法 |
| US7057062B2 (en) | 2002-04-11 | 2006-06-06 | Isis Pharmaceuticals, Inc. | Process for manufacturing purified phosphorodiamidite |
| US7030230B2 (en) * | 2002-10-25 | 2006-04-18 | Isis Pharmaceuticals, Inc. | Process of purifying phosphoramidites |
| JP2005089441A (ja) | 2003-08-08 | 2005-04-07 | Toudai Tlo Ltd | 立体規則性の高いリン原子修飾ヌクレオチド類縁体の製造法 |
| JP4580870B2 (ja) | 2003-09-02 | 2010-11-17 | 株式会社キラルジェン | リボヌクレオチド又はリボヌクレオチド誘導体の製造方法 |
| JP4616175B2 (ja) | 2003-09-02 | 2011-01-19 | 株式会社キラルジェン | ５’−ホスフィチル化モノマーおよびｈ−ホスホネートオリゴヌクレオチド誘導体の製造方法 |
| WO2005070859A1 (fr) | 2004-01-27 | 2005-08-04 | Takeshi Wada | Supports fluores et procedes de production de derives d'oligonucleotide utilisant ces supports |
| WO2005085272A1 (fr) | 2004-03-05 | 2005-09-15 | Takeshi Wada | Monomere de boranophosphate et procede de production de derive oligonucleotide |
| WO2005092909A1 (fr) | 2004-03-25 | 2005-10-06 | Toudai Tlo, Ltd. | Procédés de fabrication d'analogue ribonucléotide de forte stéréorégularité et analogue désoxyribonucléotide |
| JP2007531794A (ja) | 2004-04-05 | 2007-11-08 | アルニラム ファーマスーティカルズ インコーポレイテッド | オリゴヌクレオチドの合成および精製に使用する方法および反応試薬 |
| JP2006292394A (ja) * | 2005-04-06 | 2006-10-26 | Hiroyuki Yamane | シリカゲルの再生方法 |
| WO2009143369A2 (fr) * | 2008-05-22 | 2009-11-26 | Isis Pharmaceuticals, Inc. | Procédé de préparation de nucléosides et de leurs analogues sans utiliser de chromatographie |
| CN102282155B (zh) | 2008-12-02 | 2017-06-09 | 日本波涛生命科学公司 | 磷原子修饰的核酸的合成方法 |
| RU2612521C2 (ru) | 2009-07-06 | 2017-03-09 | Онтории, Инк. | Новые пролекарства нуклеиновых кислот и способы их применения |
| ES2586683T3 (es) | 2009-09-16 | 2016-10-18 | Wave Life Sciences Japan, Inc. | Grupo protector novedoso para sintetizar ARN y derivados del mismo |
| JP2011121881A (ja) | 2009-12-09 | 2011-06-23 | Nippon Shinyaku Co Ltd | ホスホロアミダイト化合物の製造法 |
| JP5847700B2 (ja) | 2010-03-05 | 2016-01-27 | 株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ | リボヌクレオシドホスホロチオエートの製造方法 |
| JP2011184318A (ja) | 2010-03-05 | 2011-09-22 | Univ Of Tokyo | リボヌクレシドｈ−ボラノホスホネート |
| JP5868324B2 (ja) | 2010-09-24 | 2016-02-24 | 株式会社Wave Life Sciences Japan | 不斉補助基 |
| JP6093924B2 (ja) | 2010-11-30 | 2017-03-15 | 株式会社Wave Life Sciences Japan | ２’−ｏ−修飾ｒｎａ |
| CN103796657B (zh) | 2011-07-19 | 2017-07-11 | 波涛生命科学有限公司 | 合成官能化核酸的方法 |
| CN102675386B (zh) * | 2011-12-24 | 2014-07-02 | 河南科技大学 | 一种龙胆苦苷分离提纯方法 |
| KR102213609B1 (ko) | 2012-07-13 | 2021-02-08 | 웨이브 라이프 사이언시스 리미티드 | 키랄 제어 |
| PL2872485T3 (pl) | 2012-07-13 | 2021-05-31 | Wave Life Sciences Ltd. | Asymetryczna grupa pomocnicza |
| CA2879066C (fr) | 2012-07-13 | 2019-08-13 | Shin Nippon Biomedical Laboratories, Ltd. | Adjuvant d'acide nucleique chiral |
| JPWO2015108047A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
| US10322173B2 (en) | 2014-01-15 | 2019-06-18 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
| JPWO2015108048A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| BR112016016400A2 (pt) | 2014-01-16 | 2017-10-03 | Wave Life Sciences Ltd | Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos |
| EP3943500A1 (fr) * | 2014-04-30 | 2022-01-26 | Agilent Technologies, Inc. | Groupes protecteurs phosphoreux et leurs procédés de préparation et utilisation |
| IL320434A (en) | 2015-07-22 | 2025-06-01 | Wave Life Sciences Ltd | Oligonucleotide preparations and methods |
| IL295755A (en) | 2015-10-09 | 2022-10-01 | Wave Life Sciences Ltd | Oligonucleotide compositions and methods thereof |
| CN108779132B (zh) | 2016-03-13 | 2022-04-15 | 波涛生命科学有限公司 | 用于亚磷酰胺和寡核苷酸合成的组合物和方法 |
| EP3452596A4 (fr) | 2016-05-04 | 2020-03-18 | Wave Life Sciences Ltd. | Compositions d'oligonucléotides et procédés associés |
| CN109462995A (zh) | 2016-05-04 | 2019-03-12 | 波涛生命科学有限公司 | 生物活性剂的方法和组合物 |
| JP2019520339A (ja) | 2016-06-03 | 2019-07-18 | ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． | オリゴヌクレオチド、その組成物および方法 |
| WO2018022473A1 (fr) | 2016-07-25 | 2018-02-01 | Wave Life Sciences Ltd. | Phasage |
| US11873316B2 (en) | 2016-11-23 | 2024-01-16 | Wave Life Sciences Ltd. | Compositions and methods for phosphoramidite and oligonucleotide synthesis |
| JP2020522510A (ja) | 2017-06-02 | 2020-07-30 | ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． | オリゴヌクレオチド組成物及びその使用方法 |
| CN120330183A (zh) | 2017-06-02 | 2025-07-18 | 波涛生命科学有限公司 | 寡核苷酸组合物及其使用方法 |
| CA3065523A1 (fr) | 2017-06-02 | 2018-12-06 | Wave Life Sciences Ltd. | Compositions d'oligonucleotides et leurs procedes d'utilisation |
| US11718638B2 (en) | 2017-06-21 | 2023-08-08 | Wave Life Sciences Ltd. | Compounds, compositions and methods for synthesis |
| WO2019002237A1 (fr) | 2017-06-28 | 2019-01-03 | Roche Innovation Center Copenhagen A/S | Procédé de couplage et d'oxydation multiples |
| EP3664816A4 (fr) | 2017-08-08 | 2021-05-19 | Wave Life Sciences Ltd. | Compositions oligonucléotidiques et procédés associés |
| CA3072110A1 (fr) | 2017-09-18 | 2019-03-21 | Wave Life Sciences Ltd. | Technologies de preparation d'oligonucleotides |
| EP3694530A4 (fr) | 2017-10-12 | 2021-06-30 | Wave Life Sciences Ltd. | Compositions d'oligonucléotides et procédés associés |
| SG11202009877XA (en) | 2018-04-12 | 2020-11-27 | Wave Life Sciences Ltd | Oligonucleotide compositions and methods of use thereof |
| US12391942B2 (en) | 2018-05-11 | 2025-08-19 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| JP2022513719A (ja) | 2018-12-06 | 2022-02-09 | ウェイブ ライフ サイエンシズ リミテッド | オリゴヌクレオチド組成物及びその方法 |
| CN113423385A (zh) | 2019-02-01 | 2021-09-21 | 波涛生命科学有限公司 | 寡核苷酸组合物及其方法 |
| JP2022525541A (ja) | 2019-03-20 | 2022-05-17 | ウェイブ ライフ サイエンシズ リミテッド | オリゴヌクレオチド調製に有用な技術 |
| WO2020196662A1 (fr) | 2019-03-25 | 2020-10-01 | 国立大学法人東京医科歯科大学 | Complexe d'acide nucléique double brin et son utilisation |
| BR112021021203A2 (pt) | 2019-04-25 | 2022-01-04 | Wave Life Sciences Ltd | Oligonucleotídeo; composição de oligonucleotídeo quiralmente controlada; composição farmacêutica; método para prevenir, tratar ou melhorar uma afecção, distúrbio ou doença relacionada a ush2a e/ou prevenir, atrasar o início, desenvolvimento e/ou progresso, e/ou tratar uma afecção, distúrbio ou doença relacionada a ush2a em um indivíduo suscetível à mesma ou que sofre da mesma; método para aumentar o nível de salto de um éxon prejudicial em uma transcrição de gene ush2a ou seu produto de gene em uma célula; método para prevenir, atrasar o início ou progressão de, tratar ou melhorar uma afecção, distúrbio ou doença relacionada a ush2a em um indivíduo suscetível à mesma ou que sofre da mesma; método para saltar um éxon prejudicial 13 em um alelo de ush2a em um indivíduo; método para produzir ou aumentar o nível de um éxon de proteína ush2a com salto 13 em um sistema; e composto, oligonucleotídeo, composição ou método |
| SG11202111387YA (en) | 2019-04-25 | 2021-11-29 | Wave Life Sciences Ltd | Oligonucleotide compositions and methods of use thereof |
| EP3965780A4 (fr) | 2019-05-09 | 2023-10-25 | Wave Life Sciences Ltd. | Compositions oligonucléotidiques et leurs procédés d'utilisation |
| JP2022550915A (ja) | 2019-10-06 | 2022-12-05 | ウェイブ ライフ サイエンシズ リミテッド | オリゴヌクレオチド組成物及びその使用方法 |
| JP7766589B2 (ja) | 2019-10-06 | 2025-11-10 | ウェイブ ライフ サイエンシズ リミテッド | オリゴヌクレオチド組成物及びその使用方法 |
| JP2023515862A (ja) | 2020-03-01 | 2023-04-14 | ウェイブ ライフ サイエンシズ リミテッド | オリゴヌクレオチド組成物及びその方法 |
-
2017
- 2017-03-13 CN CN201780016499.7A patent/CN108779132B/zh active Active
- 2017-03-13 AU AU2017234150A patent/AU2017234150B2/en active Active
- 2017-03-13 MA MA043822A patent/MA43822A/fr unknown
- 2017-03-13 WO PCT/US2017/022135 patent/WO2017160741A1/fr not_active Ceased
- 2017-03-13 EP EP17767279.7A patent/EP3430019A4/fr active Pending
- 2017-03-13 CA CA3015823A patent/CA3015823A1/fr active Pending
- 2017-03-13 US US16/084,556 patent/US11407775B2/en active Active
- 2017-03-13 JP JP2018567566A patent/JP7286320B2/ja active Active
- 2017-03-13 CN CN202210299677.4A patent/CN114685589A/zh active Pending
-
2018
- 2018-08-20 IL IL261247A patent/IL261247A/en unknown
-
2021
- 2021-12-14 AU AU2021286276A patent/AU2021286276B2/en active Active
-
2022
- 2022-08-05 US US17/881,956 patent/US20230136645A1/en active Pending
-
2023
- 2023-05-24 JP JP2023085661A patent/JP2023113730A/ja active Pending
-
2024
- 2024-04-16 AU AU2024202466A patent/AU2024202466A1/en active Pending
-
2025
- 2025-01-29 JP JP2025012787A patent/JP2025069269A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3430019A4 (fr) | 2019-10-30 |
| AU2024202466A1 (en) | 2024-05-02 |
| WO2017160741A1 (fr) | 2017-09-21 |
| CN108779132A (zh) | 2018-11-09 |
| AU2017234150B2 (en) | 2021-09-16 |
| US11407775B2 (en) | 2022-08-09 |
| AU2021286276B2 (en) | 2024-01-18 |
| EP3430019A1 (fr) | 2019-01-23 |
| AU2021286276A1 (en) | 2022-01-06 |
| CA3015823A1 (fr) | 2017-09-21 |
| US20190077817A1 (en) | 2019-03-14 |
| JP7286320B2 (ja) | 2023-06-05 |
| JP2023113730A (ja) | 2023-08-16 |
| CN114685589A (zh) | 2022-07-01 |
| IL261247A (en) | 2018-10-31 |
| CN108779132B (zh) | 2022-04-15 |
| JP2019510087A (ja) | 2019-04-11 |
| US20230136645A1 (en) | 2023-05-04 |
| JP2025069269A (ja) | 2025-04-30 |
| AU2017234150A1 (en) | 2018-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43822A (fr) | Compositions et procédés de synthèse de phosphoramidite et d'oligonucléotides | |
| MA46905A (fr) | Compositions et procédés de synthèse de phosphoramidites et d'oligonucléotides | |
| MA45270A (fr) | Compositions d'oligonucléotides et procédés associés | |
| MA46427A (fr) | Compositions d'oligonucléotides et procédés associés | |
| EP3630199A4 (fr) | Compositions d'oligonucléotides et leurs procédés d'utilisation | |
| EP3630788A4 (fr) | Compositions d'oligonucléotides et leurs procédés d'utilisation | |
| EP3630789A4 (fr) | Compositions d'oligonucléotides et leurs procédés d'utilisation | |
| EP3325017A4 (fr) | Compositions d'oligonucléotides et procédés associés | |
| EP3891284A4 (fr) | Compositions d'oligonucléotides et procédés associés | |
| EP3704239A4 (fr) | Compositions de casz et procédés d'utilisation | |
| IL264887B (en) | 4'-phosphate analogs and oligonucleotides comprising the same | |
| MA49578A (fr) | Incorporation de nucléotides non naturels et procédés associés | |
| HUE055458T2 (hu) | Kompozíciók és módszerek 5'-Cap RNS-ek szintézisére | |
| EP3368541A4 (fr) | Compositions et procédés d'inhibition de l'activité de l'arginase | |
| EP3350315A4 (fr) | Procédés pour l'édition autocatalytique de génome et la neutralisation de l'édition autocatalytique de génome et leurs compositions | |
| EP3484908A4 (fr) | Supports solides non nucléosides et blocs de construction de phosphoramidite pour synthèse d'oligonucléotides | |
| MA42269A (fr) | Compositions et procédés d'inhibition de l'activité de l'arginase | |
| EP3352774A4 (fr) | Compositions de flavonoïdes et procédés d'utilisation | |
| MA45688A (fr) | Compositions et procédés de potentialisation d'agents antimicrobiens | |
| EP2971034A4 (fr) | Compositions, procédés et appareil pour la synthèse d'oligonucléotides | |
| EP3349743A4 (fr) | Procédés et compositions d'inhibition de l'interaction dcn1-ubc12 | |
| EP3472354A4 (fr) | Réactions d'acides nucléiques et procédés et compositions associés | |
| EP3706558A4 (fr) | Compositions et procédés d'aquaculture | |
| EP3389673A4 (fr) | Procédés et compositions pour l'administration de polynucléotides | |
| EP3426349A4 (fr) | Procédés et compositions pour inhiber l'expression de pmp22 |